🚨 Important Update for Patients and Health Professionals: FDA Warning on #Prolia and Advanced #CKD
Attention patients, health professionals, and specialists in endocrinology, nephrology, and pharmacy: The #FDA has issued a critical update regarding the osteoporosis medication Prolia (denosumab). A completed review has concluded that Prolia increases the risk of severe hypocalcemia, particularly in patients with advanced chronic kidney disease (CKD), including those on dialysis.
Severe hypocalcemia can present with symptoms such as confusion, seizures, irregular #heart rhythm, and #muscle spasms, and can lead to hospitalization or even be life-threatening. As a result, the FDA is adding a Boxed Warning, its most prominent warning, to the Prolia prescribing information.
Patients considering or currently on Prolia treatment should discuss their kidney function and risk of severe hypocalcemia with their healthcare provider. Healthcare professionals are advised to assess patients' kidney function before prescribing Prolia and to closely monitor blood calcium levels, especially in patients with advanced CKD.
Let's spread awareness of this crucial update to ensure patient safety and effective treatment management.
Connect, Repost & Follow for more healthcare updates and recommendations 🌍
#PatientSafety #HealthcareProfessionals #Endocrinology #Nephrology #Pharmacy #FDAWarning #Prolia #ChronicKidneyDisease #PublicHealthAlert